Novartis Vs Roche
Roche eyes quick FDA approval of risdiplam for spinal muscular atrophy
The US Food and Drug Administration granted priority review for risdiplam, an oral medicine for those with the potentially deadly muscle-wasting disorder
 "Roche eyes quick FDA approval of risdiplam for spinal muscular atrophy")
Updated On : 25 Nov 2019 | 8:23 PM IST
Novartis' skin cancer drug posts win in trials, Roche flops
Novartis's mix of Tafinlar and Mekinist slashed the risk of melanoma returning or death by 53%
 "Novartis' skin cancer drug posts win in trials, Roche flops")
Updated On : 11 Sep 2017 | 12:16 PM IST
